Isomorphic Labs applies machine learning to the structural and functional prediction of biological systems, with the explicit goal of accelerating drug discovery at computational scale. Founded in 2021 as a Google DeepMind spinout, the company builds on AlphaFold - the protein structure prediction system that resolved a 50-year-old computational biology problem - to construct a unified drug design engine capable of operating across multiple therapeutic areas and molecular modalities. The core architecture treats biology as information processing, using predictive and generative models to design novel molecules and simulate drug performance before physical synthesis.
The technical stack centers on in silico workflows: computational biologists and machine learning engineers collaborate to move experimental validation cycles from wet labs to GPUs. This approach addresses the core constraint in drug discovery - the time and cost of iterative testing - by shifting candidate screening, molecular design, and preliminary efficacy modeling into deterministic prediction rather than empirical trial-and-error. Isomorphic's internal pipeline focuses on oncology and immunology, two disease areas where structural biology and molecular complexity create high barrier-to-entry advantages for predictive modeling.
The company operates under partnership agreements with Eli Lilly, Novartis, and Johnson & Johnson, signaling both validation of its platform approach and distribution into established pharmaceutical infrastructure. These collaborations allow Isomorphic to stress-test its models against real-world drug development constraints - regulatory pathways, manufacturing feasibility, off-target effects - while maintaining independence on its own therapeutic programs.